Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of two targeted therapies as a possible
treatment for acute myeloid leukemia (AML) that has relapsed after initial treatment or did
not fully respond.
The name of the study interventions involved in this study are:
- Merestinib
- LY2874455